North America Protein Expression Market Developments and Forecast by 2028
North America Protein Expression Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product (Competent Cells, Expression Vectors, Reagents, and Instruments); Services (Antibody Development & Production, Protein Expression & Production, Hybridoma One-Stop Services, Stable Cell Line Development, and Bioanalytical Assay Services); Application (Research, Therapeutic, and Industrial); End User (Pharmaceutical and Biotechnology Companies, Contract Research Organizations, Academic Research Institutes, and Others)
- Status : Published
- Report Code : TIPRE00025108
- Category : Life Sciences
- No. of Pages : 139
- Available Report Formats :
- Last update date : October 05, 2021
2021 Market Size
US$ 872.9 Mn
Base year value
2028 Forecast
US$ 1,595.9 Mn
Projected by 2028
CAGR 2022-2028
9.0 %
Growth rate
Addressable Market
US$ 8,753.85 Mn
(2022-2028)
The protein expression market in North America is expected to grow from US$ 872.9 million in 2021 to US$ 1,595.9 million by 2028; it is estimated to grow at a CAGR of 9.0% from 2021 to 2028.
The burden of dengue is rapidly increasing and will continue until the development of an effective vaccine against it. Various vaccine candidates for dengue are at preclinical and clinical trials stages of development based on different approaches. A few vaccines are a tetravalent, live attenuated virus, purified inactivated virus, recombinant proteins subunit, plasmid DNA, and virus-vectored dengue vaccines. Recent progress on recombinant subunit-based dengue vaccine candidates using various approaches, such as fusion with other immunogenic epitopes, use of a novel adjuvant, protein expression in different host systems, designer vaccine, and VLPs development, is opening new avenues for the development of a fully efficacious vaccine against dengue. Currently, more than 65 million confirmed cases and over 1.5 million deaths are reported. The COVID-19 pandemic has led to significant health, social, and economic crises. The development of a vaccine for COVID-19 is an effective strategy to control the outbreak. It is required that the vaccine is produced at high speed and is easily scalable. Recombinant protein, viral-vectored or nucleic acid-based (recombinant plasmid DNA and mRNA) vaccines need to be considered to shorten the vaccine production timeframe. The use of protein expression is increasing during vaccine development due to the advantages of recombinant protein, which drives the growth of the protein expression market.
As the current pandemic is demonstrating across the region, the pharma industry can respond robustly to the health crisis but at a cost that society may not be able to sustain under current bioprocessing development and manufacturing models. Centuries of detecting, responding, and treating pandemics have taught that if a virus (or any biologic threat) is extremely infectious and transmittable, it can spread quickly and propagate in vast numbers of people, quickly jumping social distance, borders and the ability of healthcare systems to treat the sick. The way vaccines are developed and rolled out today is about the same as it has been for the past several decades. Currently, the region mainly relies on Chinese Hamster Ovary (CHO) cells or insect cells for expression as the gold standard, but its expense and processing complexity is driving developers to consider emerging cell line (hosts in which to express these proteins and vaccines) alternatives. To help combat the Covid-19 outbreak Dyadic International, Inc. developed a hyper productive C1 cell line that produces a SARS-CoV-2 Receptor Binding Domain (RBD) antigen from the Dyadic C1 gene expression platform that expresses the RBD antigen at three grams per liter (3.5 g/l) in only four days. The impact of the COVID19 pandemic on the regional protein expression market is high.
With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the protein expression market. The North America protein expression market is expected to grow at a good CAGR during the forecast period.
- This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.
North America Protein Expression Market Segmentation
By Product
- Competent Cells
- Expression Vectors
- Reagents
- Instruments
By Services
- Antibody Development & Production
- Protein Expression & Production
- Hybridoma One-Stop Services
- Stable Cell Line Development
- Bioanalytical Assay Services
By Application
- Research
- Therapeutic
- Industrial
By End User
- Pharmaceutical and Biotechnology Companies
- Contract Research Organizations
- Academic Research Institutes
- Others
By Country
-
North America
- US
- Canada
- Mexico
Companies Mentioned
- Thermo Fisher Scientific Inc.
- GenScript
- Merck KGaA
- Agilent Technologies, Inc.
- Takara Bio Inc.
- Bio-Rad Laboratories Inc.
- QIAGEN
- New England Biolabs
- Promega Corporation
North America Protein Expression Report Scope
| Report Attribute | Details |
|---|---|
| Market size in 2021 | US$ 872.9 Million |
| Market Size by 2028 | US$ 1,595.9 Million |
| CAGR (2021 - 2028) | 9.0% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By Product
|
| Regions and Countries Covered |
North America
|
| Market leaders and key company profiles |
|
- Comprehensive Market Sizing and Forecast Analysis
- Detailed Segmentation Analysis
- In-Depth Market Dynamics Assessment
- Regional and Country-Level Insights
- Competitive Landscape and Company Benchmarking
- Strategic Business Intelligence
Recent Reports
Testimonials
The Insight Partners provided valuable market intelligence that supported our global go-to-market strategy. Their team was professional, responsive, and attentive to our feedback, providing thoughtful analysis and helpful methodological clarifications throughout the project.
Junmo Kim Chief Financial Officer (CFO), Enertech Co., Ltd.
The Insight Partners' SCADA System Market report is comprehensive, with valuable insights on current trends and future forecasts. The team was highly professional, responsive, and supportive throughout. We are very satisfied and highly recommend their services.
RAN KEDEM Partner, Reali Technologies LTDs
I requested a report on a very specific software market and the team produced the report in a few days. The information was very relevant and well presented. I then requested some changes and additions to the report. The team was again very responsive and I got the final report in less than a week.
JEAN-HERVE JENN Chairman, Future Analytica
We worked with The Insight Partners for an important market study and forecast. They gave us clear insights into opportunities and risks, which helped shape our plans. Their research was easy to use and based on solid data. It helped us make smart, confident decisions. We highly recommend them.
PIYUSH NAGPAL Sr. Vice President, High Beam Global
The Insight Partners delivered insightful, well-structured market research with strong domain expertise. Their team was professional and responsive throughout. The user-friendly website made accessing industry reports seamless. We highly recommend them for reliable, high-quality research services
YUKIHIKO ADACHI CEO, Deep Blue, LLC.
This is the first time I have purchased a market report from The Insight Partners.While I was unsure at first, I visited their web site and felt more comfortable to take the risk and purchase a market report.I am completely satisfied with the quality of the report and customer service. I had several questions and comments with the initial report, but after a couple of dialogs over email with their analyst I believe I have a report that I can use as input to our strategic planning process.Thank you so much for taking the extra time and making this a positive experience.I will definitely recommend your service to others and you will be my first call when we need further market data.
JOHN SUZUKI President and Chief Executive Officer, Board Director, BK Technologies
I wish to appreciate your support and the professionalism you displayed in the course of attending to my request for information regarding to infectious disease IVD market in Nigeria. I appreciate your patience, your guidance, and the fact that you were willing to offer a discount, which eventually made it possible for us to close a deal. I look forward to engaging The Insight Partners in the future, all thanks to the impression you have created in me as a result of this first encounter.
DR CHIJIOKE ONYIA MANAGING DIRECTOR, PineCrest Healthcare Ltd.Reason to Buy
- Informed Decision-Making
- Understanding Market Dynamics
- Competitive Analysis
- Identifying Emerging Markets
- Customer Insights
- Market Forecasts
- Risk Mitigation
- Boosting Operational Efficiency
- Strategic Planning
- Investment Justification
- Tracking Industry Innovations
- Aligning with Regulatory Trends
Get Free Sample for